Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.
The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 32094933. The webcast link is the following: Sientra Q2' 2022 Earnings Call Webcast Registration Link.
A live webcast of the conference call will be available on the Investor Relations section of the Company's website at . The webcast will be archived on the website following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company's investor relations website at .
(*) Data on file
Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com
SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.
聖巴巴拉，加利福尼亞州，2022年7月28日(環球社)--西恩特拉公司(納斯達克代碼：SEN)(以下簡稱“西恩特拉”或“公司”)，一家專注於通過提升整形手術藝術來改善生活的醫療美容公司，今天宣佈，它將在週二收盤後公佈2022年第二季度的財務業績。2022年8月11日星期四。Sientra將在同一天主持一次電話會議，討論財務業績下午4：30東部時間.
The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 32094933. The webcast link is the following: Sientra Q2' 2022 Earnings Call Webcast Registration Link.
國內來電的撥入號碼是1-866-374-5140。會議ID為32094933。網絡直播鏈接如下：Sientra Q2‘2022財報電話會議網絡直播註冊鏈接.
A live webcast of the conference call will be available on the Investor Relations section of the Company's website at . The webcast will be archived on the website following the completion of the call.
電話會議的現場網絡直播將在該公司網站的投資者關係部分進行，網址為：。電話會議結束後，網絡直播將在網站上存檔。
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
關於Sientra
Sientra總部位於加利福尼亞州聖巴巴拉，是一家專注於整形手術的醫學美學公司。該公司的使命是提供專有創新和無與倫比的合作伙伴關係，從根本上促進整形外科醫生思考、工作和護理病人的方式。Sientra開發了廣泛的產品組合，具有技術差異化的特點，並得到獨立實驗室測試和強大的臨牀試驗結果的支持。該公司的產品組合包括Sientra圓形和成型乳房植入物、FDA批准在美國銷售的第一批第五代乳房植入物、其突破性的Allx2®擁有專利的雙端口和集成引流技術的乳房組織擴張器、AuraGen脂肪移植系統和BIOCORNEUM®，整形外科醫生首選和推薦的頭號疤痕凝膠(*)。
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company's investor relations website at .
Sientra使用其投資者關係網站發佈有關公司的重要信息，包括可能被認為對投資者具有重大意義的信息。有關Sientra的財務和其他信息會定期發佈，並可在公司的投資者關係網站上訪問。
(*) Data on file
(*)數據已備案
Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com
投資者關係聯繫人
Aman R.Patel，CFA
郵箱：aman.patel@westwicke.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧